If you manage international private medical insurance (IPMI) for a workforce, renewal season can feel opaque. Premium movements are often presented as a single percentage, even though the outcome usually reflects a combination of age bands, regional pricing, benefit levels, claims trends, medical inflation, underwriting approach and currency. Benchmarking does not give you a universal “correct premium”, but it can give your HR team a repeatable way to interpret renewal terms, document decisions and communicate changes with greater confidence. This guide explains what is driving IPMI premium trends in 2026, how to benchmark responsibly using public data, and when to renegotiate without making savings promises or treating benchmarks as financial advice.
- Benchmarking is governance: it turns renewal into a documented decision, not a reaction.
- Premium movements are blended: age bands, regional pricing, plan design and claims often interact.
- Medical cost pressure remains high in 2026: public trend datasets still point to elevated healthcare cost growth.[1][2][3]
- FX can distort the picture: a budget increase in one currency may not be the same as an increase in the insurer’s billing currency.[6][8]
- Benefit levels and deductibles matter: cost-sharing affects both price and member experience.[13][14]
- Like-for-like comparison is essential: same geography, same benefits, same cost-sharing rules, same population basis.
- Renegotiation is a process: better questions, clearer documentation and structured option testing, not guaranteed outcomes.
Key pricing factors (age, location, plan type)
Employers usually experience IPMI pricing as a single renewal figure. Beneath that figure, insurers assess a broader set of variables. Public insurer materials and industry reports consistently point to age, geography, plan type, claims experience, benefit richness and currency as core premium drivers.[10][13]
Age bands
Age is rarely just a question of the average age of the group. What often matters more is how your population is distributed by age band and whether employees move into higher bands between policy years. Public insurer commentary is clear that ageing can influence premiums, although the precise impact depends on insurer methodology and product design.[10][13]
For HR, the main governance point is straightforward: if your census has aged materially, part of the renewal movement may be structural even where claims are stable. That is something to document rather than treat as an anomaly.
Location and regional pricing
In IPMI, “location” usually means both country of residence and expected care environment. It can also include the formal area of cover under the policy. These are not interchangeable.
Public medical trend reports show significant regional variation in 2026. WTW projects global medical trend at 10.3%, but with materially different regional outcomes, including 14.0% in Asia Pacific and 8.2% in Europe.[1] That matters because the same benefit schedule can price differently if your employee footprint shifts towards higher-cost or higher-trend markets.
Plan type and underwriting approach
Plan type influences price because it changes how risk is pooled and how claims are reflected. In some schemes, claims experience is a direct pricing input. In others, renewal is driven more by broader portfolio performance and rating assumptions.
From a benchmarking perspective, this is a variable to confirm rather than assume. You should record whether the scheme is broadly pooled, partly experience-rated or subject to a hybrid approach, and ask how claims are weighted in renewal pricing.
| Driver | Why it matters | How it shows up in pricing | What HR can influence | What HR cannot | What to verify |
|---|---|---|---|---|---|
| Age distribution / age bands | Age mix affects expected utilisation and claim severity. | Step changes at renewal as members move into higher age bands. | Accurate census data, dependant rules, visibility of workforce mix. | Ageing itself. | Age bands used, timing of age-step changes, whether pricing is banded or blended.[10] |
| Country of residence / regional pricing | Provider costs and treatment patterns vary by market. | Higher base rates in higher-cost countries or regions. | Accurate location data, relocation controls, correct categorisation. | Local provider pricing and healthcare inflation. | Which locations were rated, and whether remote workers were classified correctly. |
| Area of cover | Adding high-cost markets changes expected claims exposure. | Material pricing differences between worldwide and restricted cover. | Area-of-cover policy and eligibility decisions. | Hospital pricing in very high-cost markets. | What is included and excluded, including emergency treatment outside the area of cover. |
| Plan type / underwriting model | Determines whether your claims directly influence renewal terms. | Experience loadings, pooling margins or wider portfolio trend application. | Scheme structure and renewal strategy. | The insurer’s core rating methodology. | Whether the scheme is pooled, experience-rated or hybrid. |
| Claims experience | High-cost claims and frequency spikes affect loss ratios. | Greater renewal pressure, closer scrutiny, possible plan change suggestions. | Claims governance, support on appropriate treatment pathways, data review. | Random high-severity events. | Claims period used, whether outstanding or delayed claims are included, and how large claims are weighted. |
| Medical inflation / medical trend | Underlying healthcare cost growth feeds into premium assumptions. | A trend loading built into the renewal base. | Benefit design, network use, cost-sharing strategy. | Macro healthcare inflation. | Whether assumptions broadly align with credible market reports.[1][2][3] |
| Pharmaceuticals / high-cost drugs | Specialty drugs can shift claim severity quickly. | Higher outpatient or pharmacy spend and tighter authorisation controls. | Formulary design where permitted, policy definitions. | Drug launches and market pricing. | Whether pharmacy trend is cited as a driver.[1][5] |
| Benefit levels | Richer cover increases the insurer’s expected cost. | Higher premiums for higher limits, broader outpatient cover or optional modules. | Benefit design, optional benefits, limits and modules. | The unit cost of care. | Whether benefit definitions or sub-limits have changed.[13] |
| Deductibles / co-insurance / out-of-pocket maximums | Cost-sharing changes both price and utilisation behaviour. | Higher cost-sharing usually lowers premium; lower cost-sharing may increase it. | Deductible level, cost-sharing rules, employee communication. | Member behaviour in every case. | Exact mechanics, whether they apply per person or per family, and any renewal change rules.[14][16] |
| Network design / care routing | Provider contracting and direct billing capability affect costs. | Pricing differences by network tier or access rules. | Network tier choices where available. | Provider market power. | Whether network rules have changed or key providers remain available. |
| Currency / FX | Cross-currency claims and budgeting can distort apparent increases. | Renewal may look higher in budget currency even if the technical rate is stable. | Budgeting basis and FX normalisation method. | Exchange-rate movements. | Billing currency, reimbursement currency and reference rates used.[6][8][13] |
| Administration, fees and local charges | Non-claims costs can still affect total premium. | Fees, margins, local taxes or levies can change total cost. | Transparency requests, contract review. | Government-set charges or the insurer’s internal cost base. | Whether fees, commission or local charges are disclosed separately. |
| Data quality | Poor census data produces poor premium comparisons. | Mispriced categories, incorrect age/location data, weak renewal analysis. | HR data discipline and version control. | None. | Data cut-off date, inclusion rules, and treatment of joiners and leavers. |
Impact of medical inflation and currency
Medical inflation in employer health plans is usually discussed as medical trend rather than consumer inflation. In practice, this captures expected year-on-year growth in healthcare plan costs driven by provider prices, utilisation, treatment mix, pharmaceuticals and new technologies.
Multiple public datasets point to continued cost pressure in 2026. WTW projects 10.3% global medical trend for 2026, Aon forecasts 9.8%, and Mercer Marsh Benefits says medical trend is still expected to exceed 10% in most regions for a sixth consecutive year.[1][2][3] These are not IPMI premium averages, but they are useful public context when you need to assess whether a renewal explanation is broadly plausible.
The key point is not the exact percentage. It is that underlying healthcare cost pressure remains elevated, and that the pressure is uneven by region. A global workforce benchmark should therefore avoid over-averaging the environment in which your employees actually receive care.
A credible public numeric time series for universal “average IPMI premiums” is not generally available on a like-for-like basis across insurers and plan designs. The chart below therefore uses public medical trend data as a proxy for premium pressure. It is public data, but it is not a direct premium series.[1]
Global medical trend (gross) — WTW public data proxy 2024 9.5% ██████████ 2025 10.0% ███████████ 2026 10.3% ███████████▎
Source: WTW 2024–2026 Global Medical Trends Survey publications.[1]
Why currency fluctuations matter
Currency matters in at least three places in an IPMI benchmark: the insurer’s billing currency, the currency in which claims are paid or reimbursed, and your company’s internal budgeting currency. If these differ, a premium movement may look larger or smaller depending on which lens you use.
The IMF explains a nominal exchange rate as the price of one currency in terms of another.[6] The ECB similarly defines an exchange rate as the rate at which one currency can be exchanged for another.[7] That matters in IPMI because cross-border claims, imported drugs and provider contracts can all be affected by currency movements over time.
Public insurer commentary supports this mechanism. Bupa Global notes that claims may be paid in many currencies and that significant currency movements can affect future premiums because they change the cost of purchasing treatment.[13]
Research on exchange-rate pass-through also shows that currency depreciation can increase domestic prices for imports, although the strength of that effect varies by market and context.[9] For HR teams, the practical implication is not to model macroeconomics. It is to avoid confusing a technical renewal movement with a currency translation effect in internal reporting.
Keep the insurer’s billing currency as your base comparison currency so year-on-year pricing remains like for like.
Add a separate converted view for internal budgeting using a consistent public reference source such as ECB reference rates.[8]
Do not present FX translation as though it were the same as an insurer price increase. Keep those effects separate in your notes.
Effect of benefit levels and deductibles
Benchmarking quickly breaks down if you compare premiums without checking what the premium actually buys. Two plans may both be described as “international cover” or “comprehensive”, while differing materially in outpatient scope, mental health access, maternity, dental or cost-sharing rules.
Benefit levels
The most material benefit differences usually sit in inpatient and day-patient scope, outpatient inclusion and caps, diagnostic imaging, oncology definitions, mental health, maternity, dental and optical, and optional modules such as evacuation or wellness services. Public insurer guidance also makes the broader point that changes to plan benefits can contribute to premium differences.[13]
In practical terms, your benchmark should turn the table of benefits into a benefit map. If you cannot show how two plans differ on key limits, access rules and optional modules, you do not yet have a clean comparison.
Deductibles and cost-sharing
Deductibles, co-insurance and out-of-pocket limits are among the clearest design levers available to HR teams. They can influence the premium, but they also shape how members experience the plan when they need treatment.
Cigna’s public customer guide explains that choosing a deductible and/or cost share generally lowers the premium compared with a plan without those features, while also illustrating how those cost-sharing arrangements apply when a claim arises.[14] Now Health International makes a similar point: a higher deductible may reduce premium, but the trade-off is higher member out-of-pocket costs when treatment is needed.[16]
That is why deductibles should not be treated as a pure pricing lever. A change that looks modest in budget terms may feel significant to employees in markets where specialist or diagnostic costs are already high.
Renewal process caution
Not every benefit change is operationally straightforward. Public insurer documentation indicates that reducing a deductible or cost share, or otherwise enhancing cover, may trigger further medical information requests or revised restrictions depending on product rules.[14] That is not universal across every insurer, but it is common enough that HR teams should treat underwriting consequences as a checkpoint rather than an afterthought.
- Confirm inpatient/day-patient annual limits and whether major categories are fully covered or sub-limited.
- Check outpatient structure: included in full, optional, capped, visit-limited or pathway-controlled.
- Map diagnostics, scans and mental health separately rather than assuming they sit neatly within outpatient cover.
- Review maternity, newborn, dental and optical modules separately.
- Document deductible, co-insurance and out-of-pocket mechanics precisely, including whether they apply per person, per family, per year or per claim.
- Ask whether richer benefits or lower cost-sharing would trigger underwriting review at renewal.[14]
Trends for 2026 across major insurers
This section is intentionally high level. It is not a ranking and it is not a recommendation. The purpose is to summarise the main themes that appear repeatedly in credible public sources and insurer-informed trend reports.
High medical cost trend remains the core backdrop
Across WTW, Aon and Mercer Marsh Benefits, the broad message for 2026 is consistent: medical cost trend remains elevated, even if some regions are seeing modest easing from previous peaks.[1][2][3]
For HR, that means 2026 should not be treated as a normalised low-pressure year. It should be treated as an environment in which insurer pricing explanations need to be read against persistent cost pressure rather than in isolation.
Regional variation remains significant
WTW’s public reporting shows meaningful differences by region and also by country within Europe. Its Europe summary cites projected 2026 gross medical trend of 8.2% for Europe overall, while some countries sit materially above that level, including examples such as Poland, Italy and the UK.[15]
For multinational employers, this is one of the most important benchmarking points. A single “Europe” or “rest of world” label in your internal reporting may conceal real differences in pricing pressure.
What are insurers and industry sources saying drives trend?
WTW reports that insurers most frequently cite new medical technologies, decline in public healthcare systems, advances in pharmaceuticals, and fraud, waste and abuse as key contributors to medical cost trend in 2026.[1] Aon’s commentary similarly points to ongoing healthcare-specific pressures and higher utilisation as drivers of the trend environment.[5]
These stated drivers are useful because they show you what to probe. If an insurer refers broadly to “market conditions”, you can ask whether the pressure is being attributed mainly to utilisation, pharmaceuticals, technology costs, geography mix or claims-specific performance within your scheme.
New technologies and more advanced treatment pathways are repeatedly cited as cost drivers in public trend reports.[1]
Specialty drug costs and evolving clinical protocols remain an important part of cost growth in many markets.[1][5]
Where public systems are under strain, private utilisation may rise, which can feed through to employer plan costs.[1]
Tools and resources
A responsible benchmark usually combines three categories of tools: public market context, internal HR data, and insurer or broker documentation. None of these is sufficient on its own.
Public market reports
Use public medical trend reports to understand the market backdrop rather than to infer a universal premium rate. The most useful sources for 2026 include WTW, Aon and Mercer Marsh Benefits.[1][2][3]
- WTW 2026 Global Medical Trends Survey for global and regional medical trend and insurer-cited drivers.[1]
- Aon 2026 Global Medical Trend Rates reporting for regional comparisons and renewal budgeting context.[2][5]
- Mercer Marsh Benefits 2026 Health Trends reporting for global employer-plan cost context.[3][4]
FX sources
For currency normalisation, choose one reference source and apply it consistently. ECB euro foreign exchange reference rates are useful for informational benchmarking, and the ECB explicitly notes that these rates are for information purposes only.[8]
- ECB euro foreign exchange reference rates.[8]
- ECB explainer on exchange rates for non-specialist stakeholders.[7]
- IMF explanation of nominal exchange rates.[6]
Internal HR tools
You do not necessarily need specialist software. A controlled spreadsheet model, a clean HRIS export, a benefit map template and a renewal decision log may be sufficient, provided they are maintained properly.
Keep one controlled version of employee, dependant, age, location and plan tier data for each renewal cycle.
Summarise plan design differences on one page so comparisons are based on substance rather than product labels.
Record what changed, what was queried, what assumptions were accepted and who approved the final decision.
Insurer-facing requests
At renewal, it is reasonable to request:
- A written explanation of the main pricing drivers used in the renewal narrative.
- Confirmation of any changes to benefit wording, not just pricing changes.
- Two or three structured “what if” quotations, such as a higher deductible, an adjusted outpatient module or an alternative area of cover where relevant.
- Confirmation of whether any requested change would trigger underwriting review.[14]
When to renegotiate
Renegotiation in IPMI is usually less about bargaining for a headline discount and more about clarifying, testing and documenting alternatives. The objective is to decide whether the renewal terms make sense as offered, whether the design should change, or whether market testing is appropriate.
When a deeper review is justified
- A material premium movement that is not clearly explained by age mix, geography, claims or benefit changes.
- A mismatch between plan design and how employees actually use the plan.
- New employee locations or changes to area of cover.
- Noticeable shifts in claims, especially where large claims or pharmacy spend are relevant.
- Operational issues such as network gaps, pre-authorisation friction or settlement problems.
How to renegotiate responsibly
Start early. Finalise the census, benefit map and claims summary before you receive the renewal, if possible. Once the renewal arrives, compare it with your benchmark rather than reacting to the headline percentage alone.
Then request targeted options rather than a long list of permutations. In most cases, the most useful scenarios are:
- Same plan, with no design change.
- Same plan with a higher deductible or adjusted cost-sharing.
- Same core plan with selected benefit or outpatient module changes.
- An alternative area of cover where eligibility allows.
For each option, ask for the operational consequences as well as the price. That means member out-of-pocket implications, underwriting triggers, network changes and any wording changes to the table of benefits.[12][14]
- Which factors are contributing most to this renewal movement: age bands, medical trend, geography, claims experience or benefit changes?
- Have any limits, sub-limits, exclusions or authorisation rules changed in the new policy period?
- Are there any currency assumptions affecting the quoted premium or your narrative around the increase?
- If we increase the deductible or adjust the outpatient module, what changes operationally for employees?
- If we reduce the deductible or enhance benefits, will underwriting be revisited?
The benchmark for a good renegotiation is not whether the premium falls. It is whether your team validated the data, compared like with like, understood the trade-offs and documented the decision clearly. That is the most defensible way to manage renewal in a market where outcomes cannot be guaranteed.
Get Started
If you are reviewing or renewing an international employee health plan, start with the route that matches your situation. For employer scheme design, benchmarking and structured renewal support, visit Businesses & Groups. If you already have cover and want a structured review of your existing terms, use Already Covered (Review my existing policy).
For broader context on insurer comparison and the renewal process, see Choosing the Right Insurer for International Health Insurance: How to Compare What Actually Matters and Renewal strategies: managing premium increases and improving your cover.
Points to verify
- Insurer-specific trend assumptions used in renewal pricing.
- How claims experience is used: experience rating, pooled pricing or hybrid approaches.
- Whether currency is applied at billing, claims reimbursement or premium calculation stage.
- What benefit changes are permitted at renewal and when underwriting is revisited.
- Administrative fees, commission and transparency requirements by jurisdiction.
- Any regulatory constraints on benefit design in specific countries.
